Characteristics of the vaginal microbiome in women with and without clinically confirmed vulvodynia.
Adolescent
Adult
Bacteria
/ classification
Candidiasis, Vulvovaginal
/ epidemiology
Case-Control Studies
Contraceptive Agents, Hormonal
Female
Humans
Microbiota
/ physiology
Minnesota
/ epidemiology
Psychology
RNA, Ribosomal, 16S
/ analysis
Sexual Partners
Vagina
/ microbiology
Vulvodynia
/ epidemiology
Young Adult
case-control studies
microbiome
vulvodynia
yeast infections
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
15
08
2019
revised:
15
02
2020
accepted:
21
02
2020
pubmed:
7
3
2020
medline:
13
11
2020
entrez:
6
3
2020
Statut:
ppublish
Résumé
Vulvodynia (idiopathic vulvar pain) affects up to 8% of women by age 40 years, has a poorly understood etiology, and has variable treatment efficacy. Several risk factors are associated with vulvodynia from a history of yeast infections to depression and allergies. Recent work suggests an altered immune inflammatory mechanism plays a role in vulvodynia pathophysiology. Because the vaginal microbiome plays an important role in local immune-inflammatory responses, we evaluated the vaginal microbiome among women with vulvodynia compared with controls as 1 component of the immune system. The objective of the study was to characterize the vaginal microbiome in women with clinically confirmed vulvodynia and age-matched controls and assess its overall association with vulvodynia and how it may serve to modify other factors that are associated with vulvodynia as well. We conducted a case-control study of 234 Minneapolis/Saint Paul-area women with clinically confirmed vulvodynia and 234 age-matched controls clinically confirmed with no history of vulvar pain. All participants provided vulvovaginal swab samples for culture-based and non-culture (sequencing)-based microbiological assessments, background and medical history questionnaires on demographic characteristics, sexual and reproductive history, and history of psychosocial factors. Vaginal microbiome diversity was assessed using the Shannon alpha diversity Index. Data were analyzed using logistic regression. Culture and molecular-based analyses of the vaginal microbiome showed few differences between cases and controls. However, among women with alpha diversity below the median (low), there was a strong association between increasing numbers of yeast infections and vulvodynia onset, relative to comparable time periods among controls (age-adjusted odds ratio, 8.1, 95% confidence interval, 2.9-22.7 in those with 5 or more yeast infections). Also among women with low-diversity microbiomes, we observed a strong association between moderate to severe childhood abuse, antecedent anxiety, depression, and high levels of rumination and vulvodynia with odds ratios from 1.83 to 2.81. These associations were not observed in women with high-diversity microbiomes. Although there were no overall differences in microbiome profiles between cases and controls, vaginal microbiome diversity influenced associations between environmental and psychosocial risk factors and vulvodynia. However, it is unclear whether vaginal diversity modifies the association between the risk factors and vulvodynia or is altered as a consequence of the associations.
Sections du résumé
BACKGROUND
Vulvodynia (idiopathic vulvar pain) affects up to 8% of women by age 40 years, has a poorly understood etiology, and has variable treatment efficacy. Several risk factors are associated with vulvodynia from a history of yeast infections to depression and allergies. Recent work suggests an altered immune inflammatory mechanism plays a role in vulvodynia pathophysiology. Because the vaginal microbiome plays an important role in local immune-inflammatory responses, we evaluated the vaginal microbiome among women with vulvodynia compared with controls as 1 component of the immune system.
OBJECTIVE
The objective of the study was to characterize the vaginal microbiome in women with clinically confirmed vulvodynia and age-matched controls and assess its overall association with vulvodynia and how it may serve to modify other factors that are associated with vulvodynia as well.
STUDY DESIGN
We conducted a case-control study of 234 Minneapolis/Saint Paul-area women with clinically confirmed vulvodynia and 234 age-matched controls clinically confirmed with no history of vulvar pain. All participants provided vulvovaginal swab samples for culture-based and non-culture (sequencing)-based microbiological assessments, background and medical history questionnaires on demographic characteristics, sexual and reproductive history, and history of psychosocial factors. Vaginal microbiome diversity was assessed using the Shannon alpha diversity Index. Data were analyzed using logistic regression.
RESULTS
Culture and molecular-based analyses of the vaginal microbiome showed few differences between cases and controls. However, among women with alpha diversity below the median (low), there was a strong association between increasing numbers of yeast infections and vulvodynia onset, relative to comparable time periods among controls (age-adjusted odds ratio, 8.1, 95% confidence interval, 2.9-22.7 in those with 5 or more yeast infections). Also among women with low-diversity microbiomes, we observed a strong association between moderate to severe childhood abuse, antecedent anxiety, depression, and high levels of rumination and vulvodynia with odds ratios from 1.83 to 2.81. These associations were not observed in women with high-diversity microbiomes.
CONCLUSION
Although there were no overall differences in microbiome profiles between cases and controls, vaginal microbiome diversity influenced associations between environmental and psychosocial risk factors and vulvodynia. However, it is unclear whether vaginal diversity modifies the association between the risk factors and vulvodynia or is altered as a consequence of the associations.
Identifiants
pubmed: 32135142
pii: S0002-9378(20)30227-1
doi: 10.1016/j.ajog.2020.02.039
pmc: PMC10027365
mid: NIHMS1572093
pii:
doi:
Substances chimiques
Contraceptive Agents, Hormonal
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
406.e1-406.e16Subventions
Organisme : NICHD NIH HHS
ID : R01 HD058608
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Pathog Dis. 2014 Dec;72(3):161-6
pubmed: 24961922
PLoS One. 2012;7(2):e30126
pubmed: 22319561
Obstet Gynecol. 1997 Feb;89(2):291-6
pubmed: 9015038
J Low Genit Tract Dis. 2016 Apr;20(2):126-30
pubmed: 27002677
Sci Rep. 2017 Jan 04;7:39642
pubmed: 28051127
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Am J Obstet Gynecol. 2014 Jan;210(1):40.e1-8
pubmed: 24080300
Am J Obstet Gynecol. 2007 Feb;196(2):128.e1-6
pubmed: 17306651
N Engl J Med. 2005 Nov 3;353(18):1899-911
pubmed: 16267321
Crit Rev Microbiol. 2016 Nov;42(6):905-27
pubmed: 26690853
J Womens Health (Larchmt). 2017 Oct;26(10):1069-1076
pubmed: 28686502
Sci Rep. 2018 Feb 2;8(1):2307
pubmed: 29396486
Am J Obstet Gynecol. 2019 Apr;220(4):324-335
pubmed: 30447213
Ann Epidemiol. 2009 Nov;19(11):771-7
pubmed: 19825458
PLoS One. 2013 May 22;8(5):e63514
pubmed: 23717441
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Immunity. 2017 Jan 17;46(1):29-37
pubmed: 28087240
Am J Obstet Gynecol. 2016 Jan;214(1):15-21
pubmed: 26164695
J Low Genit Tract Dis. 2017 Apr;21(2):150-156
pubmed: 27984345
ISME J. 2014 Sep;8(9):1781-93
pubmed: 24599071
Eur J Obstet Gynecol Reprod Biol. 2003 Mar 26;107(1):74-7
pubmed: 12593899
ISME J. 2017 Jan;11(1):1-6
pubmed: 27636395
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Sci Rep. 2015 Mar 11;5:8988
pubmed: 25758319
J Clin Med Res. 2018 Sep;10(9):688-692
pubmed: 30116438
Obstet Gynecol. 2017 Apr;129(4):643-654
pubmed: 28277350
ISME J. 2015 Mar 17;9(4):968-79
pubmed: 25325381
PLoS One. 2013 Jul 02;8(7):e67019
pubmed: 23843979
Methods Ecol Evol. 2013 Dec 1;4(12):
pubmed: 24358444
J Sex Med. 2016 Mar;13(3):291-304
pubmed: 26944461